Specialisation
Cornea, Cataract and Refractive Surgery.
Full title
Phase II, multicentre, randomised, double-masked, 4 parallel arms, controlled, 6-month trial designed to evaluate the safety and efficacy of PAD ciclosporin (CsA 0.06% and 0.03%) ophthalmic dispersion administered once daily in combination with lubricant therapy and a 3-month post-treatment safety follow-up in moderate to severe dry eye patients.
Promoter
Biotek.
Start date
May 2016
End date
April 2019
Researchers
Principal: Dr José Luis Güell.